NCT05155332 2026-03-17
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
Clinical Trials
59 trialsNCT07090148 2026-03-11
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
Phase 1 Recruiting
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT03891953 2026-01-21
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis
Phase 1 Active not recruiting
NCT07318636 2026-01-06
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 1 Not yet recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT05631899 2025-11-24
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1 Active not recruiting
NCT02936102 2025-11-14
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04058756 2025-10-07
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase 1 Active not recruiting
NCT04000529 2025-09-30
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Phase 1 Terminated
NCT03961971 2025-09-10
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT06547957 2025-08-13
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Active not recruiting
NCT04572451 2025-08-01
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Phase 1 Recruiting
NCT03034304 2025-07-24
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
Phase 1 Terminated
NCT06377111 2025-07-14
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
University Health Network, Toronto
Phase 1 Recruiting
NCT05607953 2025-07-04
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
TriSalus Life Sciences, Inc.
Phase 1 Active not recruiting
NCT01351103 2025-06-13
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
Phase 1 Completed
NCT03294694 2025-05-31
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
NCT04581343 2025-05-04
PanCAN-SR1
Pancreatic Cancer Action Network
Phase 1 Completed
NCT03860272 2025-02-06
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Phase 1 Active not recruiting
NCT04171141 2025-01-16
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Pfizer
Phase 1 Terminated
NCT03549000 2024-12-13
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT06302062 2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1 Recruiting
NCT03716596 2024-09-20
CISPD-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Terminated
NCT03523819 2024-09-19
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT03301896 2024-06-20
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1 Terminated
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT06364787 2024-04-15
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Beijing 302 Hospital
Phase 1 Not yet recruiting
NCT02828098 2024-01-29
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Highlight Therapeutics
Phase 1 Completed
NCT02658981 2023-10-06
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT05631886 2023-08-28
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Phase 1 Recruiting
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03311412 2023-05-30
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Phase 1 Completed
NCT02452268 2023-03-03
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Novartis
Phase 1 Terminated
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
NCT02607813 2022-12-21
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Novartis
Phase 1 Terminated
NCT03064854 2022-08-15
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Novartis
Phase 1 Terminated
NCT03172936 2022-05-03
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Novartis
Phase 1 Terminated
NCT04213404 2022-04-21
RISE-HN
National Taiwan University Hospital
Phase 1 Unknown
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT03111992 2022-02-09
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT02947165 2022-01-31
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Phase 1 Completed
NCT02403193 2022-01-12
AdenONCO
Palobiofarma SL
Phase 1 Completed
NCT03176264 2021-10-12
PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
Novartis
Phase 1 Terminated
NCT04283526 2021-03-04
Study of Select Combinations in Adults With Myelofibrosis
Novartis
Phase 1 Withdrawn